Business Context and Reporting Period
This Form 8-K was filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp) on June 7, 2019. The registrant is a Delaware corporation with its principal executive offices in Irvine, California. The filing reports on a specific event under Item 8.01 (Other Events) regarding the announcement of early results from the Company's first-in-human VenoValve study.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a clinical study update and does not contain financial statements or quantitative financial data.
Material Changes
The material change reported is the issuance of a press release on June 7, 2019, announcing early results from the Company's first-in-human VenoValve study. No financial changes versus a prior period are disclosed in this text.
Guidance, Outlook, and Risks
Management Commentary: The Company highlighted the early results of its VenoValve study as a significant development. The full details of these results are contained in the press release attached as Exhibit 99.1, which is incorporated by reference.
Risks and Contingencies: The filing text does not explicitly list new risks or contingencies beyond the inherent uncertainties of clinical study results referenced in the attached exhibit.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) to understand the specific clinical outcomes of the VenoValve study.
- Confirm the registrant name is Hancock Jaffe Laboratories, Inc. (Ticker: HJLI), noting the discrepancy with the requested company name "Envveno Medical Corp."
- Review subsequent filings for any financial impact or updated guidance resulting from the study results.
- Check the status of the VenoValve study in regulatory databases to confirm the "first-in-human" designation and current phase.